Lactobacillus Acidophilus/Bifidobacterium Infantis Probiotics Are Beneficial to Extremely Low Gestational Age Infants Fed Human Milk

To evaluate the nutrition-related effects of prophylactic Lactobacillus acidophilus/ Bifidobacterium infantis probiotics on the outcomes of preterm infants <29 weeks of gestation that receive human milk and/or formula nutrition. We hypothesize that human-milk-fed infants benefit from probiotics in terms of sepsis prevention and growth. Methods: We performed an observational study of the German Neonatal Network (GNN) over a period of six years, between 1 January, 2013 and 31 December, 2018. Prophylactic probiotic use of L. acidophilus/B. infantis was evaluated in preterm infants <29 weeks of gestation (n = 7516) in subgroups stratified to feeding type: (I) Exclusively human milk (HM) of own mother and/or donors (HM group, n = 1568), (II) HM of own mother and/or donor and formula (Mix group, n = 5221), and (III) exclusive exposure to formula (F group, n = 727). The effect of probiotics on general outcomes and growth was tested in univariate models and adjusted in linear/logistic regression models. Results: 5954 (76.5%) infants received L. acidophilus/B. infantisprophylactically for the prevention of necrotizing enterocolitis (NEC). Probiotic use was associated with improved growth measures in the HM group (e.g., weight gain velocity in g/day: effect size B = 0.224; 95% CI: 2.82–4.35; p < 0.001) but not in the F group (effect size B = −0.06; 95% CI: −3.05–0.28; p = 0.103). The HM group had the lowest incidence of clinical sepsis (34.0%) as compared to the Mix group (35.5%) and the F group (40.0%). Only in the Mix group, probiotic supplementation proved to be protective against clinical sepsis (OR 0.69; 95% CI: 0.59–0.79; p < 0.001). Conclusion: Our observational data indicate that the exposure to L. acidophilus/B. infantis probiotics may promote growth in exclusively HM-fed infants as compared to formula-fed infants. To exert a sepsis-preventive effect, probiotics seem to require human milk

Cardiac anaplastic large cell lymphoma in an 8-year old boy

We report on an 8 year old boy with primary cardiac anaplastic large cell lymphoma (ALCL), in whom the diagnosis was challenging and who was treated with modified chemotherapy without radiation therapy according to the ALCL 99 study protocol [1]. Two years and 4 months after completion of therapy the boy is in complete remission with normal cardiac function

Pathogens identified by multiplex-PCR with negative blood culture result and corresponding final diagnosis.

<p>Pathogens identified by multiplex-PCR with negative blood culture result and corresponding final diagnosis.</p

Laboratory signs of infection of the VLBW cohort with suspected Late-onset sepsis (LOS).

<p>Laboratory signs of infection of the VLBW cohort with suspected Late-onset sepsis (LOS).</p

Final diagnosis of the VLBW cohort with suspected LOS episodes.

<p>Final diagnosis of the VLBW cohort with suspected LOS episodes.</p

Pathogens identified by multiplex-PCR with negative blood culture result.

<p>Pathogens identified by multiplex-PCR with negative blood culture result.</p

Pathogens identified by multiplex-PCR or blood culture.

<p>Pathogens identified by multiplex-PCR or blood culture.</p

Clinical characteristics of the VLBW cohort with suspected LOS.

<p>Clinical characteristics of the VLBW cohort with suspected LOS.</p